- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01196169
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
Daptomycin Use For Prophylaxis In Prosthetic Joint Surgery, A Randomized Prospective Study Comparing The Efficacy Of Daptomycin Versus Vancomycin For Peri-Operative Antibiotic Prophylaxis In MRSA Colonized Adult Patients Undergoing Primary Elective Hip, Knee or Shoulder Arthroplasty
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a phase 4 randomized open label prospective pilot study comparing the use of daptomycin versus vancomycin for peri-operative antibiotic prophylaxis in patients undergoing elective primary knee, hip or shoulder arthroplasty and are at risk for infection with methicillin resistant Staphylococcus aureus. The study population will include males and non-pregnant, non-lactating females 18 years of age or older, with history of methicillin-resistant Staphylococcus aureus infection or colonization, and undergoing primary elective hip, knee or shoulder arthroplasty. The target enrollment is 100 patients, who will be randomized to daptomycin or vancomycin in two 50 patient study groups. After signing the informed consent, patients will undergo pre-enrollment nasal screening for methicillin resistant Staphylococcus aureus to identify eligible patients. Patients with positive MRSA nasal screen will proceed with enrollment and get randomized into one of the two study groups. In one group, patients will receive one dose of daptomycin 6 mg/kg to be infused over 30 minutes. In this group, the infusion should be started and completed within 60 minutes of surgical incision. In the second group, patients will receive one dose of vancomycin 15 mg/kg to be infused over 1-2 hours of surgical incision according to the dose to avoid red man syndrome. In this group, the infusion should be started and completed within 120 minutes of surgical incision. After surgery, a second similar dose of vancomycin will be given 12 hours after the first dose to patients with creatinine clearance (CLcr.) of ≥50 ml/min. All patients in both groups will be asked to shower with chlorhexidine skin cleanser (HIBICLENS®) once daily from the neck down for 7days before surgery and apply Mupirocin ointment 2% to their nostrils twice daily for 5 days before surgery.
The patients will be evaluated on the day of surgery, at 2-3 days postoperatively, on discharge, at one month and three months follow up visits. During these study evaluations, patients will be assessed clinically for signs and symptoms of wound, and prosthetic joint infection (including pain, tenderness, swelling, erythema, poor wound healing and wound drainage) prior to hospital discharge, and at one, and three months follow up visits. Blood work including complete blood counts, erythrocytic sedimentation rate, c-reactive protein, and cultures will be ordered if clinical findings suggest infection. Bacterial isolates causing infections will be tested locally for antibiotic susceptibilities including daptomycin and vancomycin and saved for further testing if needed. Adverse effects and tolerability will be documented with the use of both drugs in the two patient groups. Data will be collected and analyzed with appropriate testing. The primary endpoint will be the success in prevention of postoperative SSI and prosthetic joint infection at one month postoperative follow up visit.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tennessee
-
Johnson City, Tennessee, United States, 37604
- Johnson City Medical Center
-
Mountain Home, Tennessee, United States, 37684
- James H Quillen VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed, and dated informed consent as defined by the Institutional Review Board.
- Male and female patients older than 18 years of age undergoing primary elective hip, knee or shoulder arthroplasty.
- Documented nasal carriage of MRSA.
- If a female of childbearing potential the patient should agree to practice a reliable contraceptive method (e.g. birth control pills, condoms, or intrauterine device [IUD]) during treatment and for one month after receiving the study medication.
Exclusion Criteria:
- Concurrent urinary tract infection or colonization unless treated with evidence of microbiologic cure.
- Evidence of active infection elsewhere other than urinary tract, unless treated with evidence of microbiologic cure documented by the infectious diseases service.
- Patients undergoing elective secondary arthroplasty.
- Concurrent open wounds
- Pregnant and nursing women (if patient is still of childbearing potential, a negative serum pregnancy test will be confirmed).
- History of allergy or contraindication to study drugs.
- Weight >150 kg or <50kg
- Patients with creatinine clearance (CLcr) < 30ml/min (calculated using the Cockcroft-Gault equation using ideal body weight)
- Severe neutropenia (absolute neutrophil count <0.500x103 /µl).
- Patients considered unlikely to comply with study procedures or to return for the scheduled post treatment evaluation.
- Ongoing antibiotic therapy for active infection that is anticipated to continue until the day of surgery.
- Any other condition that in the opinion of the investigator, would confound or interfere with evaluation of safety or efficacy of the investigational medication, or prevent compliance with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Daptomycin
Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
|
One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes.
The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
Other Names:
|
Active Comparator: Vancomycin
Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
|
Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose.
The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if > one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of < 50 ml/min.
Patients with creatinine clearance of < 50 ml/min will only receive one dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daptomycin efficacy in prevention of postoperative surgical site infection (SSI)
Time Frame: 24 months
|
Efficacy of daptomycin in preventing postoperative SSI will be determined for each enrolled subject on one month postoperative visit.
Overall efficacy of daptomycin among the patient group who receive it will be compared to overall efficacy of vancomycin among the second patient group who receive vancomycin upon anticipated complete enrollment study at 24 months.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of daptomycin in preventing postoperative early prosthetic joint infection
Time Frame: 30 months
|
Efficacy of daptomycin in preventing postoperative early prosthetic joint infection will be determined for each enrolled subject on three months postoperative visit.
Overall efficacy of daptomycin among the patient group who receive it will be compared to overall efficacy of vancomycin among the second patient group who receive vancomycin upon anticipated completion of the study at 30 months
|
30 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wael E Shams, M.D., James H Quillen VA Medical Center and East Tennessee State University
Publications and helpful links
General Publications
- Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004 Oct 14;351(16):1645-54. doi: 10.1056/NEJMra040181. No abstract available.
- Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup; American Academy of Orthopaedic Surgeons; American Association of Critical Care Nurses; American Association of Nurse Anesthetists; American College of Surgeons; American College of Osteopathic Surgeons; American Geriatrics Society; American Society of Anesthesiologists; American Society of Colon and Rectal Surgeons; American Society of Health-System Pharmacists; American Society of PeriAnesthesia Nurses; Ascension Health; Association of periOperative Registered Nurses; Association for Professionals in Infection Control and Epidemiology; Infectious Diseases Society of America; Medical Letter; Premier; Society for Healthcare Epidemiology of America; Society of Thoracic Surgeons; Surgical Infection Society. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004 Jun 15;38(12):1706-15. doi: 10.1086/421095. Epub 2004 May 26.
- Price CS, Williams A, Philips G, Dayton M, Smith W, Morgan S. Staphylococcus aureus nasal colonization in preoperative orthopaedic outpatients. Clin Orthop Relat Res. 2008 Nov;466(11):2842-7. doi: 10.1007/s11999-008-0337-x. Epub 2008 Jun 19.
- Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007 Oct;120(10 Suppl 1):S13-20. doi: 10.1016/j.amjmed.2007.07.010.
- Marculescu CE, Osmon DR. Antibiotic prophylaxis in orthopedic prosthetic surgery. Infect Dis Clin North Am. 2005 Dec;19(4):931-46. doi: 10.1016/j.idc.2005.07.002.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0310.7f
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcal Infections
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
GlaxoSmithKlineCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedStaphylococcal Infection
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Destiny Pharma PlcCompletedStaphylococcal InfectionUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedMethicillin-resistant Staphylococcal InfectionsFrance
-
National Institute of Allergy and Infectious Diseases...TerminatedStaphylococcal Aureus Infection | Recurrent Staphylococcal Infection | Invasive Staphylococcal InfectionUnited States
-
Aaron ChenJohns Hopkins University; Thrasher Research FundCompletedStaphylococcal Skin Infection | Abscess | Staphylococcal Infection | FolliculitisUnited States
-
Nantes University HospitalCompleted
Clinical Trials on Daptomycin
-
Cubist Pharmaceuticals LLCTerminatedWound Infections
-
Cubist Pharmaceuticals LLCCompletedGram Positive Infection | Concurrent Antibiotic TreatmentUnited States
-
Cubist Pharmaceuticals LLCCompletedBacteremia | Bacterial Endocarditis
-
University Hospital, CaenCompletedPeritoneal InfectionFrance
-
Merck Sharp & Dohme LLCCompleted
-
University of Maryland, BaltimoreCubist Pharmaceuticals LLCCompletedFasciitis, Necrotizing | Fournier's Gangrene | Severe Necrotizing Skin and Soft Tissue InfectionsUnited States
-
Cubist Pharmaceuticals LLCTerminatedGram-Positive Bacterial Infections
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompleted
-
Cubist Pharmaceuticals LLCCompleted